OMCL vs. PHR, AHCO, SLNO, BKD, IRWD, NVCR, WRBY, FDMT, VRNA, and GYRE
Should you be buying Omnicell stock or one of its competitors? The main competitors of Omnicell include Phreesia (PHR), AdaptHealth (AHCO), Soleno Therapeutics (SLNO), Brookdale Senior Living (BKD), Ironwood Pharmaceuticals (IRWD), NovoCure (NVCR), Warby Parker (WRBY), 4D Molecular Therapeutics (FDMT), Verona Pharma (VRNA), and Gyre Therapeutics (GYRE). These companies are all part of the "medical" sector.
Omnicell (NASDAQ:OMCL) and Phreesia (NYSE:PHR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.
97.7% of Omnicell shares are owned by institutional investors. Comparatively, 92.1% of Phreesia shares are owned by institutional investors. 2.6% of Omnicell shares are owned by company insiders. Comparatively, 5.8% of Phreesia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Omnicell has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Phreesia has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.
Omnicell presently has a consensus price target of $42.20, indicating a potential upside of 46.88%. Phreesia has a consensus price target of $31.62, indicating a potential upside of 45.76%. Given Omnicell's higher possible upside, analysts clearly believe Omnicell is more favorable than Phreesia.
In the previous week, Omnicell had 11 more articles in the media than Phreesia. MarketBeat recorded 15 mentions for Omnicell and 4 mentions for Phreesia. Phreesia's average media sentiment score of 0.74 beat Omnicell's score of 0.57 indicating that Phreesia is being referred to more favorably in the news media.
Omnicell has higher revenue and earnings than Phreesia. Omnicell is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks.
Omnicell has a net margin of -1.78% compared to Phreesia's net margin of -38.42%. Omnicell's return on equity of 3.43% beat Phreesia's return on equity.
Omnicell received 368 more outperform votes than Phreesia when rated by MarketBeat users. Likewise, 67.82% of users gave Omnicell an outperform vote while only 64.74% of users gave Phreesia an outperform vote.
Summary
Omnicell beats Phreesia on 11 of the 18 factors compared between the two stocks.
Get Omnicell News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Omnicell Competitors List
Related Companies and Tools
